OpGen, Inc.

179 articles with OpGen, Inc.

• OpGen Issues Formal Response to FDA’s Requests for Additional Information and Expects Near Term FDA Clearance Decision for Acuitas AMR Gene Panel

  10/13/2020

  OpGen’s Acuitas AMR Gene Panel allows testing for a very comprehensive panel of more than 40 diagnostic targets (pathogens and genetic AMR markers) in pure bacterial colonies

• OpGen Group Company Ares Genetics Wins Austrian Digitization Award for ares-genetics.cloud

  10/5/2020

  Ares Genetics wins Austrian Digitization Award for Digital Products and Solutions ares-genetics.cloud for AI-powered Antibiotic Resistance Prediction awarded by Federal Ministry for Digital and Economic Affairs VIENNA, Austria, and GAITHERSBURG, Md., Oct. 05, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today that its subsidiary Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”) has won the Austrian Digitization Award. Ares Genetics has been selected by an

• OpGen Announces Award of German Government Grant Funding to its Subsidiary Curetis and Collaborators

  9/30/2020

  Project: AI based Assay Development for carbapenem-resistance based on porin loss and efflux pump overexpression in G ram-negative bacteria Project is part of the Research Campus Infecto G nostics and includes project partners at the University Hospital Jena, Institute for Infectious Diseases and Infection Contro l GAITHERSBURG, Md., and HOLZGERLINGEN, Germany, Sept. 30, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the pow

• OpGen Announces Successful Completion of Study Collaboration with Karolinska Institutet on Bacterial Co-Infections in COVID-19 Pneumonia Patients and Presents Data on Unyvero HPN Panel at ECCVID 2020

  9/28/2020

  Rapid and accurate detection is essential to assess bacterial pneumonia co-infection in CO VID-19 critically ill patients Unyvero HPN panel demonstrated high negative predictive value (99.8% ) with potentially high clinical utility as rapid rule - out Unyvero reduces diagnostic turnaround times from days to less than 5 hours ; HPN panel viewed as a useful diagnostic tool to help with early detection  and antimicrobial stewardship GAITHERSBURG, Md. and HOLZG

• Collaborative Research by OpGen Group Company Ares Genetics and Johns Hopkins Researchers Demonstrates Potential of Next-Generation Sequencing for Investigation of Genetic Antimicrobial Resistance Mechanisms and Molecular Susceptibility Testing

  9/16/2020

  Published Study on Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance Presented Study on Long-Read Sequencing to Predict Phenotypic Antimicrobial Susceptibility Testing Results Work Aimed at Demonstrating Diagnostic Value of Next-Generation Sequencing for Antimicrobial Susceptibility Testing and Translation into Clinical Practice VIENNA, Austria and GAITHERSBURG, Md., Sept. 16, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today t

• OpGen Group Company Ares Genetics Nominated for Austrian Innovation Award for AI-powered Molecular Antibiotic Susceptibility Test

  9/8/2020

  OpGen, Inc., announced that its subsidiary Ares Genetics GmbH has been nominated for the 40th Austrian Innovation Award.

• Key Publication of Clinical Study Demonstrates Unyvero Lower Respiratory Tract (LRT) Panel is Likely to Alter Antibiotic Management of Significant Numbers of Patients Presenting with Suspected Pneumonia

  9/2/2020

  OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today the release of a new peer-reviewed publication that demonstrates the clinical utility of the Unyvero LRT panel and its potential impact on antibiotic use in hospitalized patients with suspected pneumonia compared to treatment directed based on microbiological culture results.

• OpGen Announces CE-IVD Marking and Commercial Launch in Europe of its Own Developed Molecular Diagnostic SARS-CoV-2 Kit with PULB for Detection of the Virus Causing COVID-19

  8/20/2020

  - Own developed SARS-CoV-2 Kit with PULB for COVID-19 uses real-time PCR (RT-PCR) technology on open PCR platforms, designed to provide results in approximately one hour - 100% Sensitivity and 97.3% Specificity demonstrated in isolated RNA  - Inclusion of PCR-Compatible Universal Lysis Buffer (PULB) in the kit as a workflow option allows labs to circumvent the need for extraction equipment and reagents GAITHERSBURG, Md., and HOLZGERLINGEN, Germany, Aug. 20, 2020 (GLOBE NEWSWIRE) --

• OpGen Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/12/2020

  Total Revenue for Q2 2020 was approximately $1.2 million dollars Balance sheet strengthened significantly with $6.1 million cash raised in Q2 2020 Strategic co-promotion partnership with Menarini Silicon Biosystems to market and sell Menarini’s COVID-19 related products Conference call to be held at 4:30 p.m. Eastern Time today GAITHERSBURG, Md., Aug. 12, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular di

• OpGen Co-Markets COVID-19 Antibody Test Kit

  8/9/2020

  As disclosed in OpGen, Inc.’s July 13, 2020 press release, we have commenced marketing and promotion, on a non-exclusive basis, of certain products offered by Menarini Silicon Biosystems to infectious disease healthcare providers and researchers.

• OpGen to Provide Business Update and Financial Results for the Second Quarter 2020

  8/5/2020

  OpGen, Inc. announced that the Company will provide a business update and report its second quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, August 12, 2020.

• OpGen Provides Business Update and Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2020

  7/15/2020

  Preliminary Total Revenue for Q2 2020 was approximately $1.2 million dollars Balance sheet strengthened significantly with $6.1 million cash raised in Q2 2020

• OpGen Releases Preliminary Data Demonstrating its Unyvero HPN Panel for Pneumonia Identifies Life-Threatening Bacterial Co-Infections in COVID-19 Patients in Just Five Hours

  6/9/2020

  Performance of the Unyvero HPN Panel for pneumonia proves to be strongly concordant (98.2%) compared to bacterial lower respiratory tract culture   Collaboration with Karolinska Institutet highlights critical need for rapid diagnostic tests, as one in four COVID-19 patients in the ICU had a bacterial co-infection Providing results in hours instead of days provides clinicians with early organism differential, including resistance marker information, allowing earlier treatment decisions and s

• OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections

  6/3/2020

  Project to utilize OpGen’s Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software within digital health and precision medicine platform at multiple healthcare institutions

• OpGen CEO and Chairman of the Board Issue Letters to Stockholders - May 11, 2020

  5/11/2020

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, to issued two letters to stockholders from new OpGen CEO Oliver Schacht and Chairman of the Board William Rhodes.

• OpGen Reports First Quarter 2020 Financial Results and Provides Business Update

  5/7/2020

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, reported its stand-alone financial and operating results for the three months ended March 31, 2020 and provided a business update.

• OpGen to Provide Business Update and Financial Results for the First Quarter 2020

  4/27/2020

  OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2020 financial results after the close of the U.S. financial markets on Thursday, May 7, 2020.

• OpGen Subsidiary Curetis GmbH and Karolinska Institutet Collaborate in Study of Bacterial Co-Infections in COVID-19 Pneumonia Patients

  4/21/2020

  Investigator initiated study at Sweden’s Karolinska Institutet to test COVID-19 pneumonia patients with Unyvero HPN panel for bacterial co-infections

• OpGen Subsidiary Ares Genetics Demonstrates Feasibility and Potential of Next Generation Sequencing Based Antibiotic Susceptibility Testing in Multi-Center Study

  4/16/2020

  Peer-reviewed study evaluated performance of AI-powered bioinformatics cloud platform, ares-genetics.cloud, for NGS-based antibiotic susceptibility testing on 12 pathogenic bacterial species and 21 antibiotic drugs NGS-based testing reached 100% agreement with reference culture-based testing for 32 pathogen-drug pairs and 89% across all 129 pathogen-drug combinations evaluated The comprehensive study on NGS-based antibiotic susceptibility testing was based on 620 isolates from more than

• OpGen Announces Preliminary Unaudited Revenue and Cash Position for First Quarter 2020 and Provides Business Update

  4/14/2020

  OpGen, Inc. announced that total revenue for the first quarter of 2020 was approximately $617,000 down from $1.0 million in the first quarter of 2019, excluding revenues from the Curetis businesses, which was acquired upon closing of the business combination on April 1, 2020.